Merck KGaA has partnered with German tech company AMCM to carry out clinical testing on tablets manufactured using 3D printing.
The collaboration – which could be a “massive move towards digitalization of the industry,” according to Merck’s chief strategy officer Isabel de Paoli – will focus initially on formulation development and production of 3D printed tablets for clinical trials.
Merck and AMCM – part of the metal and polymer 3D printing specialist EOS group – are working on the development of a prototype tablet printer that they hope will be ready for testing later this year.
3D printing has already reached the commercial stage in pharma, after Aprecia Pharmaceuticals claimed FDA approval for its epilepsy therapy Spritam (levetiracetam) in 2015.
